お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は、遺伝性血管性浮腫の世界市場、容量、生産量、収益、価格の概要を紹介します。2019~2023年の歴史的な市場収益/売上データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。本レポートはメーカー、地域、製品の種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、製品タイプとアプリケーション/端末業界別に遺伝性血管性浮腫市場を分類しています。
本レポートでは世界の遺伝性血管性浮腫市場の主な参加者として、企業概要、販売数量、収益、価格、粗利益率、ポートフォリオ、地理的位置、重要な発展を次のパラメータに基づいて紹介します。本研究に含まれる主な企業は：Pharming Group NV、Takeda、CSL Limited、iBio Inc.、BioCryst Pharmaceuticals, Inc.、Ionis Pharmaceuticals, Inc.

レポートは遺伝性血管性浮腫の主要生産者を調査し、主要地域や国の消費状況も提供します。遺伝性血管性浮腫の今後の市場の可能性のハイライト、およびこの市場をさまざまなセグメントおよびサブセグメントに予測するための主要な地域/国の焦点。アメリカとカナダ、中国、アジア、ヨーロッパ、中東、アフリカ、ラテンアメリカ、およびその他の国の国別データと市場価値分析。

2019年から2030年までのタイプ別および用途別、売上高、収益、価格別のセグメントデータを分析します。
タイプ別市場セグメント：
    C1 Esterase Inhibitor
    Kallikrein Inhibitor
    Selective Bradykinin B2 Receptor Antagonist

用途別の市場セグメント：
    Retail Pharmacies
    Hospital Pharmacies
    Online Pharmacies

本レポートの詳細内容
本レポートは、世界の遺伝性血管性浮腫市場の現状と将来展望を包括的に分析し、グローバルの主要地域における開発動向の綿密な調査を通じて、読者に包括的な市場分析を提示するものであります。市場の全体像を把握するために、プレイヤー、地域、製品タイプ、最終産業を網羅した多角的な分析を提供しています。さらに、世界市場のトッププレイヤーを特定し、プロファイルを作成するとともに、製品タイプや用途/最終産業に基づいて遺伝性血管性浮腫市場を細分化しています。この分類と応用により、市場の構造とダイナミクスをより深く理解することができ、情報に基づいた意思決定と戦略立案が可能になります。
一. 生産面では、2019年から2024年まで、そして2030年までの予測として、メーカー別、地域別（地域レベル、国レベル）の遺伝性血管性浮腫生産量、成長率、市場シェアを調査している。

二. 消費面では、遺伝性血管性浮腫の売上高を地域別（地域レベル・国レベル）、企業別、種類別、用途別に焦点を当てています。2019年から2024年まで、2030年までの予測。

三.主要メーカーの遺伝性血管性浮腫売上高、収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界の遺伝性血管性浮腫市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。

四.本遺伝性血管性浮腫のレポートでは関係者が市場の競争状況を包括的に理解し、事業戦略や市場戦略を的確に立てるのに役立つ洞察を提供することを目的としています。 売上高、成長動向、生産技術、用途、エンドユーザー産業の市場規模に関する詳細な評価と予測を提供し、意思決定者に強力なデータサポートを提供します。

章の概要
第1章：遺伝性血管性浮腫のレポート範囲、各市場セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメントのエグゼクティブサマリー（タイプ別およびアプリケーション別など）を紹介します。市場の現状と、短期から中期、および長期的な進化の可能性を高度に見ることができます。（2019～2030）
第2章： 遺伝性血管性浮腫の世界と主要生産者（地域／国）の生産／アウトプット。各生産者の生産量と今後6年間の発展可能性を定量的に分析しています。（2019～2030）
第3章：世界、地域、国レベルにおける遺伝性血管性浮腫の売上（消費）、収益。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界の各国の市場発展、将来の発展の見通し、市場空間を紹介します。（2019～2030）
第4章遺伝性血管性浮腫メーカーの競争状況、価格、売上高、収益、市場シェアと業界ランキング、最新の開発計画、合併、買収情報などの詳細分析。（2019～2024）
第5章：遺伝性血管性浮腫の各市場セグメントの売上高、収益、平均価格、および開発可能性をカバーした種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの売上高、収益、平均価格、発展の可能性をカバーし、読者が異なる下流市場でのブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第7章：北米（米国・カナダ）：タイプ別、用途別、国別、セグメント別の売上高、収益。（2019～2030）
第8章：ヨーロッパ：タイプ別、用途別、国別、セグメント別の売上高と収益。（2019～2030）
第9章：中国：タイプ別、アプリケーション別、セグメント別の売上高、収益。（2019～2030）
第10章：アジア（中国を除く）：タイプ別、用途別、地域別、セグメント別の売上高、収益。（2019～2030）
第11章：中東、アフリカ、中南米：タイプ別、用途別、国別、セグメント別の売上高、収益。（2019～2030）
第12章：遺伝性血管性浮腫の主要メーカーの概要を提供し、製品の説明と仕様、遺伝性血管性浮腫の売上高、収益、価格、粗利益率、最近の発展など、市場の主要企業の基本的な状況を詳細に紹介します。（2019～2024）
第13章：産業チェーン、販売チャネル、主要原材料、販売代理店および顧客の分析。
第14章：遺伝性血管性浮腫の市場動態、市場の最新の動向、市場の推進要因と制約要因、業界内のメーカーが直面する課題とリスク、業界内の関連政策の分析を紹介します。
第15章：レポートの要点と結論。

Hereditary angioedema is a rare disease and is mostly mistaken for common allergic reactions and abdominal pain. This mainly on account of the lack of knowledge among both physicians and patients about the condition. About 40% of the affected patients are diagnosed correctly with hereditary angioedema in the US and Europe. With progress in diagnostic field and different initiatives undertaken by patient bodies and industry players to spread awareness, the market for hereditary angioedema is projected to grow.
The global Hereditary Angioedema market is projected to grow from US$ 1786.9 million in 2024 to US$ 2724.1 million by 2030, at a Compound Annual Growth Rate (CAGR) of 7.3% during the forecast period.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Covers:
This report presents an overview of global market for Hereditary Angioedema, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Hereditary Angioedema, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Hereditary Angioedema, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Hereditary Angioedema sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Hereditary Angioedema market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Distribution Channel, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Hereditary Angioedema sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Pharming Group NV, Takeda, CSL Limited, iBio Inc., BioCryst Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc., etc.
Market Segmentation
By Company
    Pharming Group NV
    Takeda
    CSL Limited
    iBio Inc.
    BioCryst Pharmaceuticals, Inc.
    Ionis Pharmaceuticals, Inc.

Segment by Type
    C1 Esterase Inhibitor
    Kallikrein Inhibitor
    Selective Bradykinin B2 Receptor Antagonist

Segment by Distribution Channel
    Retail Pharmacies
    Hospital Pharmacies
    Online Pharmacies

Segment by Region
    US & Canada
        U.S.
        Canada
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
       Southeast Asia
        India
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Latin America, Middle East & Africa
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Distribution Channel, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Hereditary Angioedema in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Hereditary Angioedema manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Distribution Channel, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Distribution Channel and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Distribution Channel and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Distribution Channel, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Distribution Channel and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Distribution Channel and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hereditary Angioedema sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.

List of Tables
    Table 1. Global Hereditary Angioedema Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Table 2. Major Manufacturers of C1 Esterase Inhibitor
    Table 3. Major Manufacturers of Kallikrein Inhibitor
    Table 4. Major Manufacturers of Selective Bradykinin B2 Receptor Antagonist
    Table 5. Global Hereditary Angioedema Market Size Growth Rate by Distribution Channel, 2019 VS 2023 VS 2030 (US$ Million)
    Table 6. Global Hereditary Angioedema Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 7. Global Hereditary Angioedema Revenue by Region (2019-2024) & (US$ Million)
    Table 8. Global Hereditary Angioedema Revenue by Region (2025-2030) & (US$ Million)
    Table 9. Global Hereditary Angioedema Revenue Market Share by Region (2019-2024)
    Table 10. Global Hereditary Angioedema Revenue Market Share by Region (2025-2030)
    Table 11. Global Hereditary Angioedema Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 12. Global Hereditary Angioedema Sales by Region (2019-2024) & (K Units)
    Table 13. Global Hereditary Angioedema Sales by Region (2025-2030) & (K Units)
    Table 14. Global Hereditary Angioedema Sales Market Share by Region (2019-2024)
    Table 15. Global Hereditary Angioedema Sales Market Share by Region (2025-2030)
    Table 16. Global Hereditary Angioedema Sales by Manufacturers (2019-2024) & (K Units)
    Table 17. Global Hereditary Angioedema Sales Share by Manufacturers (2019-2024)
    Table 18. Global Hereditary Angioedema Revenue by Manufacturers (2019-2024) & (US$ Million)
    Table 19. Global Hereditary Angioedema Revenue Share by Manufacturers (2019-2024)
    Table 20. Global Key Players of Hereditary Angioedema, Industry Ranking, 2022 VS 2023 VS 2024
    Table 21. Hereditary Angioedema Price by Manufacturers 2019-2024 (USD/Unit)
    Table 22. Global Hereditary Angioedema Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 23. Global Hereditary Angioedema by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hereditary Angioedema as of 2023)
    Table 24. Global Key Manufacturers of Hereditary Angioedema, Manufacturing Base Distribution and Headquarters
    Table 25. Global Key Manufacturers of Hereditary Angioedema, Product Offered and Application
    Table 26. Global Key Manufacturers of Hereditary Angioedema, Date of Enter into This Industry
    Table 27. Mergers & Acquisitions, Expansion Plans
    Table 28. Global Hereditary Angioedema Sales by Type (2019-2024) & (K Units)
    Table 29. Global Hereditary Angioedema Sales by Type (2025-2030) & (K Units)
    Table 30. Global Hereditary Angioedema Sales Share by Type (2019-2024)
    Table 31. Global Hereditary Angioedema Sales Share by Type (2025-2030)
    Table 32. Global Hereditary Angioedema Revenue by Type (2019-2024) & (US$ Million)
    Table 33. Global Hereditary Angioedema Revenue by Type (2025-2030) & (US$ Million)
    Table 34. Global Hereditary Angioedema Revenue Share by Type (2019-2024)
    Table 35. Global Hereditary Angioedema Revenue Share by Type (2025-2030)
    Table 36. Hereditary Angioedema Price by Type (2019-2024) & (USD/Unit)
    Table 37. Global Hereditary Angioedema Price Forecast by Type (2025-2030) & (USD/Unit)
    Table 38. Global Hereditary Angioedema Sales by Distribution Channel (2019-2024) & (K Units)
    Table 39. Global Hereditary Angioedema Sales by Distribution Channel (2025-2030) & (K Units)
    Table 40. Global Hereditary Angioedema Sales Share by Distribution Channel (2019-2024)
    Table 41. Global Hereditary Angioedema Sales Share by Distribution Channel (2025-2030)
    Table 42. Global Hereditary Angioedema Revenue by Distribution Channel (2019-2024) & (US$ Million)
    Table 43. Global Hereditary Angioedema Revenue by Distribution Channel (2025-2030) & (US$ Million)
    Table 44. Global Hereditary Angioedema Revenue Share by Distribution Channel (2019-2024)
    Table 45. Global Hereditary Angioedema Revenue Share by Distribution Channel (2025-2030)
    Table 46. Hereditary Angioedema Price by Distribution Channel (2019-2024) & (USD/Unit)
    Table 47. Global Hereditary Angioedema Price Forecast by Distribution Channel (2025-2030) & (USD/Unit)
    Table 48. US & Canada Hereditary Angioedema Sales by Type (2019-2024) & (K Units)
    Table 49. US & Canada Hereditary Angioedema Sales by Type (2025-2030) & (K Units)
    Table 50. US & Canada Hereditary Angioedema Revenue by Type (2019-2024) & (US$ Million)
    Table 51. US & Canada Hereditary Angioedema Revenue by Type (2025-2030) & (US$ Million)
    Table 52. US & Canada Hereditary Angioedema Sales by Distribution Channel (2019-2024) & (K Units)
    Table 53. US & Canada Hereditary Angioedema Sales by Distribution Channel (2025-2030) & (K Units)
    Table 54. US & Canada Hereditary Angioedema Revenue by Distribution Channel (2019-2024) & (US$ Million)
    Table 55. US & Canada Hereditary Angioedema Revenue by Distribution Channel (2025-2030) & (US$ Million)
    Table 56. US & Canada Hereditary Angioedema Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 57. US & Canada Hereditary Angioedema Revenue by Country (2019-2024) & (US$ Million)
    Table 58. US & Canada Hereditary Angioedema Revenue by Country (2025-2030) & (US$ Million)
    Table 59. US & Canada Hereditary Angioedema Sales by Country (2019-2024) & (K Units)
    Table 60. US & Canada Hereditary Angioedema Sales by Country (2025-2030) & (K Units)
    Table 61. Europe Hereditary Angioedema Sales by Type (2019-2024) & (K Units)
    Table 62. Europe Hereditary Angioedema Sales by Type (2025-2030) & (K Units)
    Table 63. Europe Hereditary Angioedema Revenue by Type (2019-2024) & (US$ Million)
    Table 64. Europe Hereditary Angioedema Revenue by Type (2025-2030) & (US$ Million)
    Table 65. Europe Hereditary Angioedema Sales by Distribution Channel (2019-2024) & (K Units)
    Table 66. Europe Hereditary Angioedema Sales by Distribution Channel (2025-2030) & (K Units)
    Table 67. Europe Hereditary Angioedema Revenue by Distribution Channel (2019-2024) & (US$ Million)
    Table 68. Europe Hereditary Angioedema Revenue by Distribution Channel (2025-2030) & (US$ Million)
    Table 69. Europe Hereditary Angioedema Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 70. Europe Hereditary Angioedema Revenue by Country (2019-2024) & (US$ Million)
    Table 71. Europe Hereditary Angioedema Revenue by Country (2025-2030) & (US$ Million)
    Table 72. Europe Hereditary Angioedema Sales by Country (2019-2024) & (K Units)
    Table 73. Europe Hereditary Angioedema Sales by Country (2025-2030) & (K Units)
    Table 74. China Hereditary Angioedema Sales by Type (2019-2024) & (K Units)
    Table 75. China Hereditary Angioedema Sales by Type (2025-2030) & (K Units)
    Table 76. China Hereditary Angioedema Revenue by Type (2019-2024) & (US$ Million)
    Table 77. China Hereditary Angioedema Revenue by Type (2025-2030) & (US$ Million)
    Table 78. China Hereditary Angioedema Sales by Distribution Channel (2019-2024) & (K Units)
    Table 79. China Hereditary Angioedema Sales by Distribution Channel (2025-2030) & (K Units)
    Table 80. China Hereditary Angioedema Revenue by Distribution Channel (2019-2024) & (US$ Million)
    Table 81. China Hereditary Angioedema Revenue by Distribution Channel (2025-2030) & (US$ Million)
    Table 82. Asia Hereditary Angioedema Sales by Type (2019-2024) & (K Units)
    Table 83. Asia Hereditary Angioedema Sales by Type (2025-2030) & (K Units)
    Table 84. Asia Hereditary Angioedema Revenue by Type (2019-2024) & (US$ Million)
    Table 85. Asia Hereditary Angioedema Revenue by Type (2025-2030) & (US$ Million)
    Table 86. Asia Hereditary Angioedema Sales by Distribution Channel (2019-2024) & (K Units)
    Table 87. Asia Hereditary Angioedema Sales by Distribution Channel (2025-2030) & (K Units)
    Table 88. Asia Hereditary Angioedema Revenue by Distribution Channel (2019-2024) & (US$ Million)
    Table 89. Asia Hereditary Angioedema Revenue by Distribution Channel (2025-2030) & (US$ Million)
    Table 90. Asia Hereditary Angioedema Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 91. Asia Hereditary Angioedema Revenue by Region (2019-2024) & (US$ Million)
    Table 92. Asia Hereditary Angioedema Revenue by Region (2025-2030) & (US$ Million)
    Table 93. Asia Hereditary Angioedema Sales by Region (2019-2024) & (K Units)
    Table 94. Asia Hereditary Angioedema Sales by Region (2025-2030) & (K Units)
    Table 95. Middle East, Africa and Latin America Hereditary Angioedema Sales by Type (2019-2024) & (K Units)
    Table 96. Middle East, Africa and Latin America Hereditary Angioedema Sales by Type (2025-2030) & (K Units)
    Table 97. Middle East, Africa and Latin America Hereditary Angioedema Revenue by Type (2019-2024) & (US$ Million)
    Table 98. Middle East, Africa and Latin America Hereditary Angioedema Revenue by Type (2025-2030) & (US$ Million)
    Table 99. Middle East, Africa and Latin America Hereditary Angioedema Sales by Distribution Channel (2019-2024) & (K Units)
    Table 100. Middle East, Africa and Latin America Hereditary Angioedema Sales by Distribution Channel (2025-2030) & (K Units)
    Table 101. Middle East, Africa and Latin America Hereditary Angioedema Revenue by Distribution Channel (2019-2024) & (US$ Million)
    Table 102. Middle East, Africa and Latin America Hereditary Angioedema Revenue by Distribution Channel (2025-2030) & (US$ Million)
    Table 103. Middle East, Africa and Latin America Hereditary Angioedema Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 104. Middle East, Africa and Latin America Hereditary Angioedema Revenue by Country (2019-2024) & (US$ Million)
    Table 105. Middle East, Africa and Latin America Hereditary Angioedema Revenue by Country (2025-2030) & (US$ Million)
    Table 106. Middle East, Africa and Latin America Hereditary Angioedema Sales by Country (2019-2024) & (K Units)
    Table 107. Middle East, Africa and Latin America Hereditary Angioedema Sales by Country (2025-2030) & (K Units)
    Table 108. Pharming Group NV Company Information
    Table 109. Pharming Group NV Description and Major Businesses
    Table 110. Pharming Group NV Hereditary Angioedema Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 111. Pharming Group NV Hereditary Angioedema Product Model Numbers, Pictures, Descriptions and Specifications
    Table 112. Pharming Group NV Recent Developments
    Table 113. Takeda Company Information
    Table 114. Takeda Description and Major Businesses
    Table 115. Takeda Hereditary Angioedema Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 116. Takeda Hereditary Angioedema Product Model Numbers, Pictures, Descriptions and Specifications
    Table 117. Takeda Recent Developments
    Table 118. CSL Limited Company Information
    Table 119. CSL Limited Description and Major Businesses
    Table 120. CSL Limited Hereditary Angioedema Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 121. CSL Limited Hereditary Angioedema Product Model Numbers, Pictures, Descriptions and Specifications
    Table 122. CSL Limited Recent Developments
    Table 123. iBio Inc. Company Information
    Table 124. iBio Inc. Description and Major Businesses
    Table 125. iBio Inc. Hereditary Angioedema Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 126. iBio Inc. Hereditary Angioedema Product Model Numbers, Pictures, Descriptions and Specifications
    Table 127. iBio Inc. Recent Developments
    Table 128. BioCryst Pharmaceuticals, Inc. Company Information
    Table 129. BioCryst Pharmaceuticals, Inc. Description and Major Businesses
    Table 130. BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 131. BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Product Model Numbers, Pictures, Descriptions and Specifications
    Table 132. BioCryst Pharmaceuticals, Inc. Recent Developments
    Table 133. Ionis Pharmaceuticals, Inc. Company Information
    Table 134. Ionis Pharmaceuticals, Inc. Description and Major Businesses
    Table 135. Ionis Pharmaceuticals, Inc. Hereditary Angioedema Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 136. Ionis Pharmaceuticals, Inc. Hereditary Angioedema Product Model Numbers, Pictures, Descriptions and Specifications
    Table 137. Ionis Pharmaceuticals, Inc. Recent Developments
    Table 138. Key Raw Materials Lists
    Table 139. Raw Materials Key Suppliers Lists
    Table 140. Hereditary Angioedema Distributors List
    Table 141. Hereditary Angioedema Customers List
    Table 142. Hereditary Angioedema Market Trends
    Table 143. Hereditary Angioedema Market Drivers
    Table 144. Hereditary Angioedema Market Challenges
    Table 145. Hereditary Angioedema Market Restraints
    Table 146. Research Programs/Design for This Report
    Table 147. Key Data Information from Secondary Sources
    Table 148. Key Data Information from Primary Sources
List of Figures
    Figure 1. Hereditary Angioedema Product Picture
    Figure 2. Global Hereditary Angioedema Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Hereditary Angioedema Market Share by Type in 2023 & 2030
    Figure 4. C1 Esterase Inhibitor Product Picture
    Figure 5. Kallikrein Inhibitor Product Picture
    Figure 6. Selective Bradykinin B2 Receptor Antagonist Product Picture
    Figure 7. Global Hereditary Angioedema Market Size Growth Rate by Distribution Channel, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 8. Global Hereditary Angioedema Market Share by Distribution Channel in 2023 & 2030
    Figure 9. Retail Pharmacies
    Figure 10. Hospital Pharmacies
    Figure 11. Online Pharmacies
    Figure 12. Hereditary Angioedema Report Years Considered
    Figure 13. Global Hereditary Angioedema Revenue, (US$ Million), 2019 VS 2023 VS 2030
    Figure 14. Global Hereditary Angioedema Revenue 2019-2030 (US$ Million)
    Figure 15. Global Hereditary Angioedema Revenue Market Share by Region in Percentage: 2023 Versus 2030
    Figure 16. Global Hereditary Angioedema Revenue Market Share by Region (2019-2030)
    Figure 17. Global Hereditary Angioedema Sales 2019-2030 ((K Units)
    Figure 18. Global Hereditary Angioedema Sales Market Share by Region (2019-2030)
    Figure 19. US & Canada Hereditary Angioedema Sales YoY (2019-2030) & (K Units)
    Figure 20. US & Canada Hereditary Angioedema Revenue YoY (2019-2030) & (US$ Million)
    Figure 21. Europe Hereditary Angioedema Sales YoY (2019-2030) & (K Units)
    Figure 22. Europe Hereditary Angioedema Revenue YoY (2019-2030) & (US$ Million)
    Figure 23. China Hereditary Angioedema Sales YoY (2019-2030) & (K Units)
    Figure 24. China Hereditary Angioedema Revenue YoY (2019-2030) & (US$ Million)
    Figure 25. Asia (excluding China) Hereditary Angioedema Sales YoY (2019-2030) & (K Units)
    Figure 26. Asia (excluding China) Hereditary Angioedema Revenue YoY (2019-2030) & (US$ Million)
    Figure 27. Middle East, Africa and Latin America Hereditary Angioedema Sales YoY (2019-2030) & (K Units)
    Figure 28. Middle East, Africa and Latin America Hereditary Angioedema Revenue YoY (2019-2030) & (US$ Million)
    Figure 29. The Hereditary Angioedema Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023
    Figure 30. The Top 5 and 10 Largest Manufacturers of Hereditary Angioedema in the World: Market Share by Hereditary Angioedema Revenue in 2023
    Figure 31. Global Hereditary Angioedema Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 32. Global Hereditary Angioedema Sales Market Share by Type (2019-2030)
    Figure 33. Global Hereditary Angioedema Revenue Market Share by Type (2019-2030)
    Figure 34. Global Hereditary Angioedema Sales Market Share by Distribution Channel (2019-2030)
    Figure 35. Global Hereditary Angioedema Revenue Market Share by Distribution Channel (2019-2030)
    Figure 36. US & Canada Hereditary Angioedema Sales Market Share by Type (2019-2030)
    Figure 37. US & Canada Hereditary Angioedema Revenue Market Share by Type (2019-2030)
    Figure 38. US & Canada Hereditary Angioedema Sales Market Share by Distribution Channel (2019-2030)
    Figure 39. US & Canada Hereditary Angioedema Revenue Market Share by Distribution Channel (2019-2030)
    Figure 40. US & Canada Hereditary Angioedema Revenue Share by Country (2019-2030)
    Figure 41. US & Canada Hereditary Angioedema Sales Share by Country (2019-2030)
    Figure 42. U.S. Hereditary Angioedema Revenue (2019-2030) & (US$ Million)
    Figure 43. Canada Hereditary Angioedema Revenue (2019-2030) & (US$ Million)
    Figure 44. Europe Hereditary Angioedema Sales Market Share by Type (2019-2030)
    Figure 45. Europe Hereditary Angioedema Revenue Market Share by Type (2019-2030)
    Figure 46. Europe Hereditary Angioedema Sales Market Share by Distribution Channel (2019-2030)
    Figure 47. Europe Hereditary Angioedema Revenue Market Share by Distribution Channel (2019-2030)
    Figure 48. Europe Hereditary Angioedema Revenue Share by Country (2019-2030)
    Figure 49. Europe Hereditary Angioedema Sales Share by Country (2019-2030)
    Figure 50. Germany Hereditary Angioedema Revenue (2019-2030) & (US$ Million)
    Figure 51. France Hereditary Angioedema Revenue (2019-2030) & (US$ Million)
    Figure 52. U.K. Hereditary Angioedema Revenue (2019-2030) & (US$ Million)
    Figure 53. Italy Hereditary Angioedema Revenue (2019-2030) & (US$ Million)
    Figure 54. Russia Hereditary Angioedema Revenue (2019-2030) & (US$ Million)
    Figure 55. China Hereditary Angioedema Sales Market Share by Type (2019-2030)
    Figure 56. China Hereditary Angioedema Revenue Market Share by Type (2019-2030)
    Figure 57. China Hereditary Angioedema Sales Market Share by Distribution Channel (2019-2030)
    Figure 58. China Hereditary Angioedema Revenue Market Share by Distribution Channel (2019-2030)
    Figure 59. Asia Hereditary Angioedema Sales Market Share by Type (2019-2030)
    Figure 60. Asia Hereditary Angioedema Revenue Market Share by Type (2019-2030)
    Figure 61. Asia Hereditary Angioedema Sales Market Share by Distribution Channel (2019-2030)
    Figure 62. Asia Hereditary Angioedema Revenue Market Share by Distribution Channel (2019-2030)
    Figure 63. Asia Hereditary Angioedema Revenue Share by Region (2019-2030)
    Figure 64. Asia Hereditary Angioedema Sales Share by Region (2019-2030)
    Figure 65. Japan Hereditary Angioedema Revenue (2019-2030) & (US$ Million)
    Figure 66. South Korea Hereditary Angioedema Revenue (2019-2030) & (US$ Million)
    Figure 67. China Taiwan Hereditary Angioedema Revenue (2019-2030) & (US$ Million)
    Figure 68. Southeast Asia Hereditary Angioedema Revenue (2019-2030) & (US$ Million)
    Figure 69. India Hereditary Angioedema Revenue (2019-2030) & (US$ Million)
    Figure 70. Middle East, Africa and Latin America Hereditary Angioedema Sales Market Share by Type (2019-2030)
    Figure 71. Middle East, Africa and Latin America Hereditary Angioedema Revenue Market Share by Type (2019-2030)
    Figure 72. Middle East, Africa and Latin America Hereditary Angioedema Sales Market Share by Distribution Channel (2019-2030)
    Figure 73. Middle East, Africa and Latin America Hereditary Angioedema Revenue Market Share by Distribution Channel (2019-2030)
    Figure 74. Middle East, Africa and Latin America Hereditary Angioedema Revenue Share by Country (2019-2030)
    Figure 75. Middle East, Africa and Latin America Hereditary Angioedema Sales Share by Country (2019-2030)
    Figure 76. Brazil Hereditary Angioedema Revenue (2019-2030) & (US$ Million)
    Figure 77. Mexico Hereditary Angioedema Revenue (2019-2030) & (US$ Million)
    Figure 78. Turkey Hereditary Angioedema Revenue (2019-2030) & (US$ Million)
    Figure 79. Israel Hereditary Angioedema Revenue (2019-2030) & (US$ Million)
    Figure 80. GCC Countries Hereditary Angioedema Revenue (2019-2030) & (US$ Million)
    Figure 81. Hereditary Angioedema Value Chain
    Figure 82. Hereditary Angioedema Production Process
    Figure 83. Channels of Distribution
    Figure 84. Distributors Profiles
    Figure 85. Bottom-up and Top-down Approaches for This Report
    Figure 86. Data Triangulation
    Figure 87. Key Executives Interviewed